Seriously there are times we wonder whether our wine drinking friends in France have the capacity to learn. One just might think that by now they would understand that the insulin market has commoditized. That with the introduction of Basaglar from Lilly (NYSE: LLY) that when it comes to long-acting insulin it’s all about price and has nothing to do with performance. But as Momma Kliff used to say; “Just because something is obvious does not mean people will accept reality”.
We mention this as this morning we read that Sanofi (NYSE: SNY) is touting the benefits of . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.